Ozempic — semaglutide, FDA-approved for type 2 diabetes.

Ozempic is semaglutide (Novo Nordisk) formulated for type 2 diabetes. FDA-approved in 2017. Same active molecule as Wegovy, but labeled for glycemic control rather than chronic weight management. Max dose is 2mg/week (Wegovy goes to 2.4mg).

The off-label use of Ozempic for weight management without T2DM is what drove the supply shortages of 2022–2024. We prescribe Ozempic for its labeled indication (T2DM) and prescribe Wegovy or compounded semaglutide for weight management without diabetes — the legally and clinically cleaner approach.

Same semaglutide mechanism as Wegovy — GLP-1 receptor agonist, slows gastric emptying, glucose-dependent insulin secretion, suppressed glucagon, central satiety effects.

For T2DM specifically, the value comes from improved HbA1c (typically 1–2% reduction), weight loss as a secondary benefit (5–10%), and reduced cardiovascular events in patients with established cardiovascular disease.

Ozempic tends to fit:

• Patients with type 2 diabetes (FDA-labeled indication)
• Patients with T2DM and established cardiovascular disease (FDA-labeled cardiovascular indication)
• T2DM patients where metformin alone isn't producing target HbA1c

For patients without T2DM seeking weight management, Wegovy or compounded semaglutide are the appropriate prescriptions — not Ozempic. We don't prescribe Ozempic off-label for weight loss; the supply pressure on T2DM patients is real.

Four-step escalation: 0.25mg → 0.5mg → 1mg → 2mg, once weekly, increasing every 4 weeks. Many T2DM patients respond fully at 0.5 or 1mg and don't need to escalate to the max dose.

HbA1c reduction: typically 1–2 percentage points within 6 months. Weight loss: typically 5–10% as a secondary benefit. Cardiovascular benefit: established in patients with prior CV events. Side effects: GI-related, same profile as Wegovy.

Ozempic is prescribed for its labeled T2DM indication. We coordinate with your existing endocrinologist or PCP where relevant and don't duplicate care unnecessarily. For patients without T2DM looking for semaglutide-based weight management, see the Wegovy or compounded semaglutide options — same molecule, different label that maps to what you actually need.